Form 4: Adverum Biotechnologies Director Reports Merger-Related Changes

Adverum Biotechnologies director Dawn Svoronos reported changes in beneficial ownership following the company's acquisition by Eli Lilly and Company, effective December 9, 2025.

Summary

• Adverum Biotechnologies, Inc. was acquired by Eli Lilly and Company, with the merger becoming effective on December 9, 2025.
• The acquisition was executed through a tender offer by Flying Tigers Acquisition Corporation, a wholly-owned subsidiary of Eli Lilly.
• Tendering stockholders received $3.56 per share in cash, plus one non-tradable contingent value right (CVR) for each share.
• Each CVR represents the contractual right to receive up to two contingent cash payments totaling an aggregate of $8.91 per CVR, subject to specified milestone achievements.
• Following the tender offer, Flying Tigers Acquisition Corporation merged into Adverum Biotechnologies, Inc., making Adverum a wholly-owned subsidiary of Eli Lilly.
• Out-of-the-money stock options (exercise price equal to or greater than $3.56) were fully vested and then cancelled for no consideration at the effective time of the merger.
• Cash-out stock options (exercise price less than $3.56) were cancelled in exchange for a cash payment equal to the difference between the cash consideration and the exercise price, multiplied by the number of shares, plus one CVR for each share subject to the option.

Sentiment

Score: 7

Explanation: The sentiment is positive for former shareholders due to the immediate cash payment and potential upside from CVRs, representing a successful exit. However, the company ceases to exist as an independent entity, which could be seen as a neutral to slightly negative aspect for those invested in its standalone growth story.

Positives

• Shareholders received immediate cash consideration of $3.56 per share.
• Shareholders received contingent value rights (CVRs) offering potential additional payments of up to $8.91 per CVR upon achievement of specified milestones.
• The acquisition by a major pharmaceutical company like Eli Lilly provides a clear exit strategy and liquidity for Adverum shareholders.

Negatives

• Adverum Biotechnologies, Inc. ceased to be an independent publicly traded company.
• Out-of-the-money stock options were cancelled for no consideration, resulting in no value for holders of those options.

Risks

• The contingent value rights (CVRs) are non-tradable and their payments are entirely dependent on the achievement of specified milestones, which may not occur.
• The value of the CVRs is uncertain and could be zero if milestones are not met.

Future Outlook

Adverum Biotechnologies, Inc. is now a wholly-owned subsidiary of Eli Lilly and Company. Its future operations and strategic direction will be integrated into Eli Lilly's broader corporate strategy, with potential contingent payments to former shareholders based on specific milestone achievements.

Industry Context

This acquisition reflects a broader trend in the biotechnology and pharmaceutical industries where larger, established pharmaceutical companies acquire smaller biotech firms to expand their pipeline, gain access to innovative therapies, and consolidate market position. The use of contingent value rights (CVRs) is a common mechanism in such deals to bridge valuation gaps and share future development risks and rewards.

Comparison to Industry Standards

• The acquisition structure, involving a tender offer followed by a merger, is a standard approach for corporate takeovers in the biotechnology sector.
• The inclusion of a Contingent Value Right (CVR) is a common feature in biotech acquisitions, particularly when the acquired company's pipeline assets have significant but uncertain future value, similar to deals seen with companies like Celgene (acquired by Bristol-Myers Squibb) or Spark Therapeutics (acquired by Roche), where CVRs were used to provide additional upside tied to regulatory approvals or sales milestones.

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash consideration and CVRs, providing liquidity and potential future upside.
• Employees: Adverum employees are now part of the Eli Lilly organization, subject to Eli Lilly's corporate structure and policies.
• Customers/Partners: Future relationships and product development will be managed under Eli Lilly's strategic direction.

Next Steps

• Monitoring the achievement of specified milestones for potential contingent cash payments under the CVR Agreement.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Eli Lilly, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Stock Options, Biotechnology, Pharmaceuticals